Madrigal Pharmaceuticals (MDGL) Competitors

$518.87 +8.61 (+1.69%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$506.50 -12.37 (-2.38%)

As of 08:41 AM Eastern

MDGL vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you buy Madrigal Pharmaceuticals stock or one of its competitors? MarketBeat compares Madrigal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Madrigal Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market.

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 20 mentions for Madrigal Pharmaceuticals and 17 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.42 beat Madrigal Pharmaceuticals' score of 0.14 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.29B	9.08	$313.75M	$3.66	79.64
Madrigal Pharmaceuticals	$1.13B	10.56	-$288.28M	-$12.80	N/A

Alnylam Pharmaceuticals has a net margin of 11.72% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

Alnylam Pharmaceuticals currently has a consensus target price of $471.96, suggesting a potential upside of 61.92%. Madrigal Pharmaceuticals has a consensus target price of $687.00, suggesting a potential upside of 32.40%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

Summary

Alnylam Pharmaceuticals beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Biogen has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market.

In the previous week, Biogen had 8 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 28 mentions for Biogen and 20 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 0.91 beat Madrigal Pharmaceuticals' score of 0.14 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	12 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.94B	3.04	$1.29B	$9.32	21.95
Madrigal Pharmaceuticals	$1.13B	10.56	-$288.28M	-$12.80	N/A

Biogen has a net margin of 13.81% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Biogen's return on equity of 12.83% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

Biogen currently has a consensus target price of $214.23, suggesting a potential upside of 4.74%. Madrigal Pharmaceuticals has a consensus target price of $687.00, suggesting a potential upside of 32.40%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.50
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

Summary

Biogen beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Madrigal Pharmaceuticals' net margin of -27.32%. United Therapeutics' return on equity of 19.24% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
United Therapeutics	40.62%	19.24%	17.25%

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Madrigal Pharmaceuticals presently has a consensus target price of $687.00, indicating a potential upside of 32.40%. United Therapeutics has a consensus target price of $619.42, indicating a potential upside of 6.88%. Given Madrigal Pharmaceuticals' higher probable upside, research analysts clearly believe Madrigal Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.13B	10.56	-$288.28M	-$12.80	N/A
United Therapeutics	$3.17B	7.76	$1.33B	$27.09	21.39

In the previous week, United Therapeutics had 11 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 31 mentions for United Therapeutics and 20 mentions for Madrigal Pharmaceuticals. United Therapeutics' average media sentiment score of 0.39 beat Madrigal Pharmaceuticals' score of 0.14 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	14 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

United Therapeutics beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Incyte?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Incyte has a net margin of 26.71% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Incyte's return on equity of 26.66% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
Incyte	26.71%	26.66%	19.77%

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Madrigal Pharmaceuticals presently has a consensus target price of $687.00, indicating a potential upside of 32.40%. Incyte has a consensus target price of $104.26, indicating a potential upside of 5.51%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Incyte has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.13B	10.56	-$288.28M	-$12.80	N/A
Incyte	$5.14B	3.84	$1.29B	$7.08	13.96

In the previous week, Madrigal Pharmaceuticals had 9 more articles in the media than Incyte. MarketBeat recorded 20 mentions for Madrigal Pharmaceuticals and 11 mentions for Incyte. Incyte's average media sentiment score of 0.78 beat Madrigal Pharmaceuticals' score of 0.14 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incyte	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Incyte beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neurocrine Biosciences has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.13B	10.56	-$288.28M	-$12.80	N/A
Neurocrine Biosciences	$2.86B	5.67	$478.60M	$6.49	24.86

In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 20 mentions for Madrigal Pharmaceuticals and 13 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.86 beat Madrigal Pharmaceuticals' score of 0.14 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Neurocrine Biosciences has a net margin of 21.55% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Neurocrine Biosciences' return on equity of 19.79% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Madrigal Pharmaceuticals presently has a consensus target price of $687.00, indicating a potential upside of 32.40%. Neurocrine Biosciences has a consensus target price of $184.15, indicating a potential upside of 14.15%. Given Madrigal Pharmaceuticals' higher possible upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Neurocrine Biosciences beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDGL vs. The Competition

Export

Metric	Madrigal Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.96B	$3.05B	$6.31B	$12.29B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-40.54	18.86	21.03	25.62
Price / Sales	10.56	284.53	551.42	75.98
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	22.01	4.35	9.76	6.66
Net Income	-$288.28M	$72.19M	$3.55B	$333.63M
7 Day Performance	-2.99%	-1.05%	-0.53%	-0.12%
1 Month Performance	-1.17%	-0.02%	1.20%	3.93%
1 Year Performance	83.44%	46.31%	41.21%	36.07%

Madrigal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDGL Madrigal Pharmaceuticals	2.977 of 5 stars	$518.87 +1.7%	$687.00 +32.4%	+75.7%	$11.96B	$1.13B	N/A	90	Analyst Forecast Analyst Revision
ALNY Alnylam Pharmaceuticals	4.5141 of 5 stars	$284.84 -3.5%	$471.96 +65.7%	+9.2%	$39.39B	$3.71B	77.83	2,770
BIIB Biogen	3.0642 of 5 stars	$197.95 +2.3%	$214.23 +8.2%	+66.1%	$28.56B	$9.89B	21.24	7,500
UTHR United Therapeutics	3.5498 of 5 stars	$569.88 +0.9%	$619.42 +8.7%	+88.1%	$23.98B	$3.18B	21.04	1,400	Insider Trade
INCY Incyte	4.5351 of 5 stars	$100.32 +1.8%	$104.26 +3.9%	+62.5%	$19.69B	$5.14B	14.17	2,844

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDGL) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Summary

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Summary

How does Madrigal Pharmaceuticals compare to Incyte?

Summary

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Madrigal Pharmaceuticals (MDGL) Competitors

MDGL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Madrigal Pharmaceuticals compare to Alnylam Pharmaceuticals?

Which has more volatility & risk, ALNY or MDGL?

Does the media prefer ALNY or MDGL?

Do insiders and institutionals hold more shares of ALNY or MDGL?

Which has higher valuation & earnings, ALNY or MDGL?

Is ALNY or MDGL more profitable?

Do analysts recommend ALNY or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to Biogen?

Which has more volatility and risk, BIIB or MDGL?

Does the media prefer BIIB or MDGL?

Do institutionals and insiders hold more shares of BIIB or MDGL?

Which has stronger earnings & valuation, BIIB or MDGL?

Is BIIB or MDGL more profitable?

Do analysts recommend BIIB or MDGL?

Summary

How does Madrigal Pharmaceuticals compare to United Therapeutics?

Which has more risk & volatility, MDGL or UTHR?

Is MDGL or UTHR more profitable?

Do insiders & institutionals believe in MDGL or UTHR?

Do analysts rate MDGL or UTHR?

Which has preferable earnings & valuation, MDGL or UTHR?

Does the media favor MDGL or UTHR?

Summary

How does Madrigal Pharmaceuticals compare to Incyte?

Which has more risk & volatility, MDGL or INCY?

Is MDGL or INCY more profitable?

Do insiders & institutionals believe in MDGL or INCY?

Do analysts rate MDGL or INCY?

Which has preferable earnings & valuation, MDGL or INCY?

Does the media favor MDGL or INCY?

Summary

How does Madrigal Pharmaceuticals compare to Neurocrine Biosciences?

Do insiders & institutionals believe in MDGL or NBIX?

Which has better valuation and earnings, MDGL or NBIX?

Does the media refer more to MDGL or NBIX?

Which has more volatility and risk, MDGL or NBIX?

Is MDGL or NBIX more profitable?

Do analysts rate MDGL or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL vs. The Competition

Madrigal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools